Drug Approval | August 16, 2022
Lupin receives approval from U.S. FDA for Meclizine Hydrochloride Tablets USP
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
Meclizine Hydrochloride Tablets had estimated annual sales of USD 29 million in the U.S.
The product will be manufactured at Lupin’s facility in Goa, India.
Investment in response to increased demand for North American-based chemistry services
EBITDA stood at Rs. 39.9 crore and EBITDA margin for the quarter was 38.2% whereas Profit After Tax (PAT) stood at Rs. 17.5 crore translating into a PAT margin of 16.7%
Margins under pressure - Price erosion, shelf stock adjustments and inventory pare down in US biz impacted margins.
The inspection concluded with four Form 483 observations. None of the observations were related to data integrity.
The 562,000 square feet facility has been recognized as the first and largest integrated insulin manufacturer in Malaysia by MBR
Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.
Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million
The total financial outlay of the scheme is Rs.500 crore for a period of five years from 2021-22 to 2025-26.
Subscribe To Our Newsletter & Stay Updated
